CONNECT WITH US
HealthTech

HealthTech

Stryker lowers 2026 guidance after slowdown in hip, knee procedures

MedTech Dive logo

Published on

Add as a preferred source on Google
Stryker lowers 2026 guidance after slowdown in hip, knee procedures

CEO Kevin Lobo said the slowdown in hip and knee procedures is tied to broader economic concerns. The outgoing CEO also detailed the company’s decision to partner with CMR Surgical.

Stryker is facing a slowdown in joint replacement procedures, which CEO Kevin Lobo attributed to a broader market deceleration.

The company reported fewer hip and knee procedures in the third quarter than expected, with knee sales growing 1.1% in the quarter compared with the year-ago period and hip sales decreasing by 1%.

“Beginning with hips and knees, it is now clear that there is a market slowdown,” Lobo said in a Thursday earnings call. “In the U.S., we are seeing slower procedural growth amid affordability concerns from higher insurance premiums and deductibles.”

CFO Preston Wells first flagged the slower sales at an event last month. While Stryker has grappled with a cyberattack this year and a new software implementation within its orthopedics business, Lobo attributed the numbers to a slow market and economic challenges.

The company hasn’t lost business in hips and knees to the competition, Lobo said, but patients are delaying the procedures due to insurance costs and pre-authorization denials.

“There are patients that today are having trouble being able to make their deductible because their deductibles are higher,” Lobo said. “They’re actually living with pain a little bit longer than they would like to.”

He added that the market for joint replacement procedures has historically been tied to economic cycles.

0%. 3%.



Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.